Statin use and kidney cancer outcomes: A propensity score analysis
详细信息 查看全文
- 作者：Madhur Nayan ; M.D. ; C.M.a ; b ; Antonio Finelli ; M.D. ; M.Sc.a ; b ; Michael A.S. Jewett ; M.D.a ; b ; David N. Juurlink ; M.D. ; Ph.D.c ; Peter C. Austin ; Ph.D.d ; e ; f ; Girish S. Kulkarni ; M.D. ; Ph.D.a ; b ; Robert J. Hamilton ; M.D. ; M.P.H.a ; b ; rob.hamilton@uhn.ca" class="auth_mail" title="E-mail the corresponding author
- 关键词：HMG-CoA reductase inhibitor ; Kidney neoplasms ; Nephrectomy ; Propensity score ; Survival
- 刊名：Urologic Oncology: Seminars and Original Investigations
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：34
- 期：11
- 页码：487.e1-487.e6
- 全文大小：270 K
文摘
- •
Statin use has been associated with improved survival outcomes in various cancers.
- •
However, studies in renal cell carcinoma (RCC) have demonstrated conflicting results.
- •
We used propensity score methods to evaluate this association in M0, patients with RCC.
- •
Statin use was not associated with any of the survival outcomes evaluated.
- •
Population-based studies are needed to further evaluate statins in RCC.